Form 8-K - Current report:
SEC Accession No. 0001104659-24-028467
Filing Date
2024-02-28
Accepted
2024-02-28 07:07:49
Documents
15
Period of Report
2024-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247349d1_8k.htm   iXBRL 8-K 30601
2 EXHIBIT 99.1 tm247349d1_ex99-1.htm EX-99.1 51936
  Complete submission text file 0001104659-24-028467.txt   263132

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20240228.xsd EX-101.SCH 3012
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20240228_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20240228_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT tm247349d1_8k_htm.xml XML 3491
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 24690142
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)